CE Quiz Pharmacists – Diabetes: Be Nice CE - Diabetes 2015: Be Nice to Diabetics Pharmacist - 0278-0000-15-041-H01-P 1Contact2Quiz Name* First Last Email* Phone* What is the appropriate route and dosage form of Afrezza®?* Oral disintegrating tablet Oral inhalation powder Nasal inhalation mist Nasal inhalation powder Afrezza® is contraindicated in which type of patients?* Patients with Type 1 diabetes Patients with Type 2 diabetes Patients with asthma and COPD Patients with chronic bronchitis What is the black boxed warning associated with Synjardy®?* Lactic acidosis Heart failure risk Liver failure Severe joint pain What is the new warning issued for DPP-4 inhibitors?* Lactic acidosis Heart failure risk Liver failure Severe joint pain Someone experiencing the above concern from DPP-4 inhibitors should:* Stop taking the medication right away Switch to a different DPP-4 inhibitor Be evaluated by their physician right away Be told the symptoms will never go away Which of the following combinations would be appropriate for a patient with diabetes on the maximum dose of Xigduo® XR?* 2 tablets of Xigduo® XR 5/500mg 2 tablets of Xigduo® XR 5/1000mg 2 tablets of Xigduo® XR 10/500mg 2 tablets of Xigduo® XR 10/1000mg What of the following is true about Afrezza®?* It is a long-acting insulin and should be used right before a meal is eaten It should be used with a rapid-acting insulin in patients with Type 1 diabetes It is a rapid-acting insulin and should be used right after a meal is eaten It should be used with a long-acting insulin in patients with Type 1 diabetes What is the new warning issued for canagliflozin (Invokana®, Invokamet®)?* Increased bone mineral density Increased lung function problems Decreased bone mineral density Decreased lung function capacity What is the mechanism of action of SGLT-2 inhibitors?* Decrease reabsorption of glucose via SGLT-2 in the kidneys Inhibit degradation of endogenous incretins in the body Decrease excretion of glucose (glucosuria) from the kidneys Increase glucagon secretion and gastric emptying What is the mechanism of action of DPP-4 inhbitors?* Decrease reabsorption of glucose via SGLT-2 in the kidneys Inhibit degradation of endogenous incretins in the body Decrease excretion of glucose (glucosuria) from the kidneys Increase glucagon secretion and gastric emptying Δ
